PMID- 15793803
OWN - NLM
STAT- MEDLINE
DCOM- 20050812
LR  - 20161124
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 94
IP  - 5
DP  - 2005 May
TI  - Effect of piceatannol in human monocyte-derived dendritic cells in vitro.
PG  - 974-82
AB  - Piceatannol is an anti-inflammatory, immunomodulatory, and antiproliferative 
      stilbene that has been shown to interfere with the cytokine signaling pathway. 
      Dendritic cells (DCs) play a pivotal in the initiation of T-cell-mediated immune 
      responses, making them an attractive cellular adjuvant for use in cancer 
      vaccines. This study investigated the effect of piceatannol on the phenotypic and 
      functional maturation of human monocyte-derived DCs in vitro. Human monocytes 
      were cultured with GM-CSF and IL-4 for 6 days, followed by another 2 days in the 
      presence of piceatannol or LPS. DCs harvested on day 8 were examined using 
      functional assays. The expression levels of CD1a, CD80, CD83, and CD86 as 
      expressed by mean fluorescence intensity (MFI) on DCs differentiated from 
      immature DCs after culture with 1 muM of piceatannol for 2 days were enhanced and 
      decreased endocytic activity. Piceatannol-treated DCs also displayed enhanced 
      T-cell stimulatory capacity in a MLR, as measured by T-cell proliferation. 
      Similar results were obtained with DCs differentiated with LPS from immature DCs. 
      However, piceatannol did not inhibit phenotypic and functional maturation induced 
      by LPS from immature DCs. Piceatannol-treated DCs induced the differentiation of 
      naive T cells towards a helper T-cell type 1 (Th1) response at DCs/T (1:5) cells 
      ratio depending on IL-12 secretion. These results demonstrate that piceatannol 
      may be used on DC-based vaccine for cancer immunotherapy.
CI  - Copyright 2005 Wiley-Liss, Inc
FAU - Takei, Masao
AU  - Takei M
AD  - Division of Cellular Allergology, Research Center Borstel, Parkallee 22, D-23845, 
      Borstel, Germany. mtakei@fz-horstel.de
FAU - Umeyama, Akemi
AU  - Umeyama A
FAU - Arihara, Shigenobu
AU  - Arihara S
FAU - Matsumoto, Hitoshi
AU  - Matsumoto H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Culture Media)
RN  - 0 (Cytokines)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Stilbenes)
RN  - 187348-17-0 (Interleukin-12)
RN  - 6KS3LS0D4F (3,3',4,5'-tetrahydroxystilbene)
SB  - IM
MH  - Antibodies, Monoclonal/pharmacology
MH  - Cell Differentiation/drug effects
MH  - Coculture Techniques
MH  - Culture Media
MH  - Cytokines/metabolism
MH  - Dendritic Cells/*drug effects
MH  - Fluorescent Antibody Technique
MH  - Humans
MH  - Interleukin-12/metabolism
MH  - Lipopolysaccharides/pharmacology
MH  - Lymphocyte Culture Test, Mixed
MH  - Monocytes/*drug effects
MH  - Phenotype
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Stilbenes/*pharmacology
MH  - T-Lymphocytes/drug effects
MH  - T-Lymphocytes, Helper-Inducer/drug effects
EDAT- 2005/03/29 09:00
MHDA- 2005/08/13 09:00
CRDT- 2005/03/29 09:00
PHST- 2005/03/29 09:00 [pubmed]
PHST- 2005/08/13 09:00 [medline]
PHST- 2005/03/29 09:00 [entrez]
AID - S0022-3549(16)31761-0 [pii]
AID - 10.1002/jps.20279 [doi]
PST - ppublish
SO  - J Pharm Sci. 2005 May;94(5):974-82. doi: 10.1002/jps.20279.